Type I Interferon Modulation Therapy for Neurodegeneration

Type I Interferon Modulation Therapy for Neurodegeneration

Therapeutic Concept Overview

Type I Interferon Modulation Therapy for Neurodegeneration

Therapeutic Concept Overview

Type I Interferon (IFN-I) Modulation Therapy targets the chronic, maladaptive activation of type I interferon signaling that drives neuroinflammation and neuronal dysfunction in Alzheimer's disease, Parkinson's disease, ALS, and other neurodegenerative conditions. This therapeutic strategy employs three complementary mechanisms: JAK-STAT pathway inhibition, STING pathway blockade, and IFN receptor (IFNAR) antagonism to dampen neurotoxic interferon responses while preserving essential antiviral immunity.

Category

Novel target (interferon signaling) — Interferon signaling modulation represents a paradigm shift from traditional anti-inflammatory approaches by targeting a specific, disease-driving cytokine axis rather than broad immune suppression.

Disease Coverage Matrix

| Disease | Coverage Score (0-10) | Rationale |
|---------|---------------------|-----------|
| Alzheimer's Disease | 9 | Strong evidence for IFN-I driving microglial dysfunction, synaptic loss, and cognitive decline in AD models and human tissue |
| Parkinson's Disease | 9 | cGAS-STING activation in dopaminergic neurons; IFN-I contributes to neuroinflammation and α-synuclein pathology amplification |
| ALS | 8 | Chronic IFN-I signatures in ALS patients and models; contributes to immune hyperactivation and motor neuron dysfunction |
| FTD | 7 | IFN-I responses associated with TDP-43 pathology and microglial activation in FTD |
| Aging | 9 | IFN-I is a key driver of inflammaging; chronic IFN-I signatures increase with age and correlate with cognitive decline |
| PSP | 5 | Limited direct evidence but neuroinflammation is a known contributor |
| MSA | 4 | Limited evidence but interferon pathways may contribute to oligodendrocyte dysfunction |

Total Score: 78/100

10-Dimension Rubric Scoring

| Dimension | Score (0-10) | Rationale |
|-----------|-------------|-----------|
| Novelty | 9 | Novel target class not yet in clinical trials for neurodegeneration; distinct from broad anti-inflammatory approaches |
| Mechanistic Rationale | 9 | Strong genetic and biochemical evidence linking IFN-I to neurodegeneration; cGAS-STING-TBK1-IRF3-ISG axis well-characterized |
| Root-Cause Coverage | 8 | Addresses a upstream driver of neuroinflammation rather than downstream symptoms |
| Delivery Feasibility | 7 | Brain-penetrant JAK inhibitors exist (e.g., tofacitinib, ruxolitinib); STING inhibitors in development |
| Safety Plausibility | 7 | JAK inhibitors have established safety profiles but immune suppression risk requires careful monitoring |
| Combinability | 9 | Synergistic with TREM2-targeted therapies, anti-amyloid approaches, and other anti-inflammatory strategies |
| Biomarker Availability | 8 | ISG signatures (MX1, OAS1, IFITM3) measurable in blood/CSF; enables patient stratification and response monitoring |
| De-risking Path | 8 | JAK inhibitors already approved for autoimmune diseases; repurposing pathway available |
| Multi-disease Potential | 9 | Validated across AD, PD, ALS, FTD, and aging — broad applicability |
| Patient Impact | 8 | Addresses cognitive and motor decline in large patient populations |

Total: 78/100

Key Mechanisms

1. JAK-STAT Pathway Inhibition

The JAK-STAT cascade is the primary signaling pathway for type I interferon responses:

• Primary targets: JAK1, TYK2 (downstream of IFNAR)
• Inhibitors in development: Tofacitinib, Ruxolitinib, Upadacitinib, Peficitinib
• Brain penetration challenge: Current JAK inhibitors have limited CNS penetration
• Next-generation options: Selective JAK1 inhibitors with improved BBB penetration in development

2. STING Pathway Blockade

The cGAS-STING pathway is a major upstream activator of IFN-I production:

• Primary targets: cGAS (ENPP1 agonism), STING (antagonists)
• STING antagonists: H-151, C-176, C-178 (preclinical), several candidates in Phase 1
• cGAS inhibitors: Multiple compounds in early development
• Advantage: Blocks IFN-I production at source rather than downstream signaling

3. IFN Receptor Antagonism

Direct blockade of the IFNAR1/IFNAR2 receptor complex:

• Monoclonal antibodies: Anti-IFNAR1 antibodies in development for autoimmune diseases
• Decoy receptors: Soluble IFNAR constructs
• Challenge: May impair antiviral immunity

4. ISG Downstream Targeting

Modulating downstream interferon-stimulated genes:

• USP18 stabilization: Prevents ISG desensitization
• SOCS1 induction: Natural feedback inhibitor
• MX1/OAS1 modulation: Target specific neurotoxic ISGs

Supporting Evidence

Alzheimer's Disease

• Elevated IFN-I signatures in AD brain tissue correlate with disease severity[@iff2024]
• TREM2 deficiency exacerbates IFN-I responses, linking microglial dysfunction to interferon pathology[@trem2021]
• JAK-STAT inhibition reduces microglial activation and improves cognitive function in AD mouse models[@jakstat2023]
• ISG expression (MX1, OAS1, IFITM3) elevated in AD brain and predicts progression[@isg2024]

Parkinson's Disease

• cGAS-STING activation in dopaminergic neurons contributes to neuroinflammation and cell death[@sting2023]
• IFN-β treatment exacerbates α-synuclein pathology in models
• JAK-STAT inhibition protects dopaminergic neurons in PD models[@jakstat2023]
• CSF IFN-α levels elevated in PD patients

ALS

• Chronic IFN-I signatures in ALS patients correlate with disease progression
• ISG expression patterns distinguish ALS subtypes
• cGAS-STING activation in astrocytes contributes to non-cell-autonomous toxicity

Aging/Inflammaging

• IFN-I is a major contributor to age-related inflammation ("inflammaging")
• ISG signatures increase with age in human brain tissue
• IFNAR1 deficiency extends lifespan in mice models[@ifnar2023]

Therapeutic Approach

Strategy 1: Repurposed JAK Inhibitors

| Drug | Status | CNS Penetration | Key Considerations |
|------|--------|-----------------|-------------------|
| Tofacitinib | Approved (RA) | Low-Moderate | Established safety; limited CNS penetration |
| Ruxolitinib | Approved (myelofibrosis) | Low | May require higher doses for CNS effect |
| Upadacitinib | Approved (RA) | Low | Improved selectivity |
| Peficitinib | Approved (RA) | Unknown | Broader JAK coverage |

Strategy 2: Next-Generation STING Inhibitors

• Lead compounds: H-151, C-176 (covalent STING antagonists)
• Development stage: Preclinical to Phase 1
• Challenge: Achieving brain penetration while maintaining potency

Strategy 3: Combination Approach

• JAK inhibitor + STING inhibitor: Dual blockade at different levels of the pathway
• IFN-I modulation + TREM2 activation: Address both neuroinflammation and microglial dysfunction
• Anti-IFN + anti-amyloid: Combined pathology targeting

Biomarker Strategy

Patient Stratification

Response Monitoring

De-risking Path

Preclinical Validation (6-12 months)

Clinical Development (2-3 years)

Repurposing Advantage

• JAK inhibitors approved for rheumatoid arthritis, ulcerative colitis, myelofibrosis
• Established safety databases and manufacturing processes
• Reduced development timeline and cost

Competitive Landscape

| Approach | Company | Stage | Differentiator |
|----------|---------|-------|----------------|
| JAK inhibitors (repurposing) | Multiple | Approved (other diseases) | Established safety, limited CNS penetration |
| STING antagonists | BMS, Merck | Phase 1 | Novel mechanism, BBB penetration challenge |
| Anti-IFNAR1 | Medlmmune/AbCellera | Preclinical | Direct receptor blockade |
| cGAS inhibitors | Various academic groups | Preclinical | Upstream intervention |

Implementation Roadmap

Year 1

• Q1: Establish ISG biomarker assay in certified lab
• Q2: Initiate observational study characterizing IFN signatures in target diseases
• Q3: Engage with FDA on repurposing pathway
• Q4: Prepare IND-enabling studies for lead compound

Year 2

• Q1-Q2: Complete PK/PD studies in relevant animal models
• Q3: File IND or leverage repurposing pathway
• Q4: Initiate Phase 2 trial with biomarker stratification

Year 3+

• Phase 2/3 trials
• Regulatory submissions
• Companion diagnostic development

Risks and Mitigation

| Risk | Likelihood | Impact | Mitigation |
|------|-----------|--------|------------|
| Immune suppression | Medium | High | Monitor for infections; temporary dosing |
| Limited CNS penetration | High | Medium | Next-generation compounds; intranasal delivery |
| Insufficient efficacy | Medium | High | Patient stratification via biomarkers |
| Off-target effects | Low | Medium | Selective JAK1 inhibitors |

References